{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-250357","form_type":"8-K","ticker":"ALXO","cik":"0001810182","company_name":"ALX ONCOLOGY HOLDINGS INC","filed_at":"2023-10-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.579725+00:00","generated_at":"2026-06-10T04:55:33.525195+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ALX Oncology reports positive interim Phase 2 ASPEN-06 data for evorpacept in HER2+ gastric cancer","bullets":["Confirmed ORR 52% for evorpacept combo vs 22% control; median DOR not reached vs 7.4 months.","First positive randomized data for any CD47 blocker in solid tumors; safety consistent with prior trials.","Phase 3 ASPEN-06 initiation planned late 2024; final Phase 2 results expected Q2 2024.","Stratification factors (2nd/3rd line, prior ENHERTU) prespecified and balanced per protocol."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-250357","json":"https://secwatch.observer/filing/0001193125-23-250357.json","markdown":"https://secwatch.observer/filing/0001193125-23-250357.md","text":"https://secwatch.observer/filing/0001193125-23-250357.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810182/000119312523250357/0001193125-23-250357-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810182/000119312523250357/d539238d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T04:55:33.525195+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}